SWITZERLAND – Roche has announced that its Cobas Pulse system is now available in select European countries that accept CE mark approval.
Roche created the Cobas Pulse system to combine the form factor of a high-performance blood glucose meter with the ease of use and expanded digital capabilities of a smartphone. The platform is now part of Roche’s portfolio of connected point-of-care solutions.
According to a press release, the Cobas Pulse system can be used in a variety of care settings that require timely and informed clinical decisions.
Furthermore, Roche claims that it can improve bedside care by simplifying workflows for busy nurses and doctors.
Cobas Pulse includes clinically useful digital health applications based on the Android operating system. It provides decision support as well as vital sign and digital biomarker measurements.
Smart, Roche’s newest module in the Cobas Infinity Edge suite of software solutions, enables the platform’s selected apps.
“Frontline health workers are under increasing pressure to not only accurately diagnose patients, but also make appropriate decisions on all aspects of disease management and patient care,” said Thomas Schinecker, CEO, Roche Diagnostics.
The Big Pharma’s diagnostics division tapped diabetes cloud provider Glytec to supply software for the device—its Glucommander insulin-dosing program—to help streamline the complex task of managing blood sugar levels during a patient’s hospital stay.
The cobas pulse hand-held device includes an automated glucose test strip reader, as well as a camera and touchscreen for logging other diagnostic results, all housed in a hardened body that can be disinfected. It is intended for use with patients of all ages, including newborns and those in intensive care.
Glytec’s Glucommander was approved by the FDA in 2006, and it has since become an integral part of the company’s eGlycemic Management System, a medical decision support program for insulin titration.
It has modules for inpatients receiving nutrition through a feeding tube and can recommend doses for a variety of insulins administered intravenously or subcutaneously.
According to Glytec, the software has been shown to reduce episodes of severely low blood sugar by 99.8 percent while also lowering the rate of readmissions and the length of hospital stays.
The cobas pulse aims to improve clinician workflow by running the Glucommander dosing software on the blood sugar reader itself.
The company has several collaborations, such as Smart4Diagnostics, imito, decide, CardioSignal, and SteadySense, and plans to seek CE In Vitro Diagnostic Regulation (CE IVDR) and FDA clearance for the Cobas Pulse system in other markets over the next year.